Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Biosimilars: SOP for Emergency Shutdown of Bioreactor – V 2.0

Posted on By


Biosimilars: SOP for Emergency Shutdown of Bioreactor – V 2.0


Standard Operating Procedure for Emergency Shutdown of Bioreactor in Biosimilar Manufacturing

Department Biosimilars
SOP No. SOP/BS/118/2025
Supersedes SOP/BS/118/2022
Page No. Page 1 of 11
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To provide a standardized procedure for safely shutting down a bioreactor in case of an emergency during upstream biosimilar manufacturing, including power failure, equipment malfunction, contamination, or personnel safety threats.

2. Scope

This SOP applies to all bioreactors used in biosimilar upstream processing, including seed and production-scale vessels operating under batch, fed-batch, or perfusion modes.

3. Responsibilities

  • Operator: Initiate emergency shutdown procedure and notify responsible authorities.
  • Engineering: Assess and resolve root cause, support safe handling of equipment.
  • QA: Review incident documentation and ensure compliance with deviation handling SOP.

4. Accountability

The Head of Manufacturing is accountable for ensuring that emergency shutdown procedures are executed correctly and deviations are documented.

5. Procedure

5.1 Triggers for Emergency Shutdown

  1. Sudden power failure or UPS malfunction.
  2. Sensor failure or critical alarm for DO, pH, temperature, or agitation.
  3. Risk of contamination due to gasket/tubing breach.
  4. Spillage, fire, or personal safety hazard in vicinity.

5.2 Immediate Response

  1. Press the Emergency Stop (E-Stop) on the bioreactor control panel.
  2. Disconnect power if electrical hazard is suspected.
  3. Close all manual inlet/outlet valves to isolate the vessel.
  4. Stop feed pump and aeration to prevent overpressure or foaming.

5.3 Notification and Escalation

  1. Inform the shift supervisor and QA immediately.
  2. Log the alarm code, time, and system message from SCADA or HMI.
  3. Escalate to Maintenance and EHS for joint inspection if personnel or facility risk is present.

5.4 Containment and Assessment

  1. Inspect vessel status and secure lid/port areas.
  2. Take sample (if safe) for microbial/chemical testing.
  3. Document status in Annexure-1: Emergency Shutdown Checklist.

5.5 Recovery or Disposition

  1. If safe and authorized, restart after Engineering clearance using SOP for restart (referenced separately).
  2. If batch is compromised, coordinate with QA for batch rejection and cleanout using standard decontamination procedure.

5.6 Documentation

  1. Fill Annexure-2: Emergency Shutdown Log.
  2. Initiate deviation report and investigation within 24 hours.

6. Abbreviations

  • SCADA: Supervisory Control and Data Acquisition
  • QA: Quality Assurance
  • UPS: Uninterruptible Power Supply
  • EHS: Environment, Health, and Safety

7. Documents

  1. Emergency Shutdown Checklist – Annexure-1
  2. Emergency Shutdown Log – Annexure-2

8. References

  • WHO TRS 999 Annex 2 – GMP for Biologicals
  • ICH Q9 – Quality Risk Management
  • Internal SOP for Restart of Bioreactors (Ref: SOP/BS/090/2025)

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Emergency Shutdown Checklist

Checkpoint Status (Y/N) Remarks
Emergency Stop Pressed Y Manual shutdown confirmed
Valves Closed Y All ports isolated
Feed Pumps Off Y Confirmed by HMI

Annexure-2: Emergency Shutdown Log

Date Time Reason Operator Immediate Action Escalated To
04/05/2025 04:30 Power failure Ajay Verma Isolated vessel Maintenance & QA

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Added shutdown checklist and clarified restart authority Audit recommendation
See also  Biosimilars: SOP for Reduction and Alkylation (if applicable) - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: API Manufacturing: SOP for Issuance of Controlled Copies of SOPs – V 2.0
Next Post: Creams: SOP for Conducting Root Cause Analysis for Product Failures – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version